Semin Thromb Hemost 2005; 31(2): 195-204
DOI: 10.1055/s-2005-869525
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: +1(212) 584-4662.

Preclinical and Clinical Studies with Selective Reversible Direct P2Y12 Antagonists

J. J.J van Giezen1 , Robert G. Humphries2
  • 1Associate Principle Scientist, AstraZeneca Mölndal, Mölndal, Sweden
  • 2AstraZeneca Charnwood, Loughborough, United Kingdom
Further Information

Publication History

Publication Date:
26 April 2005 (online)

ABSTRACT

An important role for adenosine diphosphate (ADP)-induced platelet activation and aggregation was proposed more than 40 years ago. The clinical use of clopidogrel, a prodrug of an irreversible P2Y12 antagonist, has further proved the relevance of inhibiting signaling via the platelet-specific P2Y12 ADP receptor in the prevention of cardiovascular events. Pharmacological studies at AstraZeneca R&D Charnwood have identified direct, selective, and competitive P2Y12 antagonists, including cangrelor (also known as AR-C69931MX), which is suitable for intravenous administration, and AZD6140, which is suitable for oral administration. In preclinical use, these compounds predictably and effectively inhibited platelet aggregation without significant increases in bleeding time. In clinical use, these compounds may have significant advantages over current antiplatelet agents. This article summarizes preclinical and clinical data on cangrelor and AZD6140 and discusses the potential of these compounds as novel antiplatelet therapies.

REFERENCES

 Dr.
Johan J.J van Giezen

AstraZeneca R&D Mölndal, Department of Integrative Pharmacology

Pepparedsleden 1, S-431 83 Mölndal, Sweden

Email: Hans.vanGiezen@astrazeneca.com